AI assistant
ORTHOCELL LIMITED — Capital/Financing Update 2017
Jan 8, 2017
65477_rns_2017-01-08_fe490fee-58c2-4354-9a1e-34767afba39f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [595 x 111] intentionally omitted <==
Orthocell receives $1,947,998 R&D tax incentive refund
Perth, Australia; 09 January 2017: Regenerative medicine company Orthocell Limited (“the Company”) is pleased to announce that it has received a Research and Development (R&D) tax incentive cash refund of $1,947,998 for the financial year 2015/2016.
The R&D Tax Incentive is an Australian Government program to support Australian companies to undertake research and development in Australia under which eligible companies can receive cash rebates of up to 45% of eligible expenditure on research and development activities.
ENDS
For more information, please contact:
General enquiries
Investor and Media enquiries
Paul Anderson Ben Walsh Orthocell Limited, Managing Director WE Buchan P: +61 8 9360 2888 P: + 61 411 520 012 E: [email protected] E: [email protected]
About Orthocell Limited
Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGAapproved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.
Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au